PD-1 Immunotherapy Resistance Linked With Pathway Defects

Share this content:
Acquired resistance to PD-1 blockade immunotherapy of patients with melanoma may be associated with defects in the pathways.
Acquired resistance to PD-1 blockade immunotherapy of patients with melanoma may be associated with defects in the pathways.

Acquired resistance to programmed death 1 (PD-1) blockade immunotherapy of patients with melanoma may be associated with defects in the pathways that are involved in interferon-receptor signaling and in antigen presentation, according to a study published in The New England Journal of Medicine.1

Researchers analyzed biopsy samples from paired baseline and relapsing lesions in 4 patients with metastatic melanoma to examine the mechanisms of immune-resistance in cancer progression.

The patients had an initial objective tumor regression in response to anti-PD-1 therapy with pembrolizumab, followed by disease progression months or years later.

Upon whole-exome sequencing, the researchers detected clonal selection and outgrowth of the resistant tumors. Two of the 4 patients had resistance-associated loss-of-function mutations in the genes that encoded interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2).

A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient.

RELATED: Nivolumab Associated With Better QoL Than Dacarbazine for Patients with Advanced Melanoma

The JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, which included insensitivity to its antiproliferative effects on cancer cells. The B2M truncating mutation led to a loss of surface expression of major histocompatibility complex class I.

Reference

  1. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. 13 Jul 2016. N Engl J Med. doi: 10.1056/NEJMoa1604958 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters